Last updated on June 2019

An Efficacy Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma


Brief description of study

The purpose of this study is to compare the effect of ixazomib + dexamethasone (ixa + dex) versus pomalidomide + dexamethasone (pom + dex) on progression-free survival (PFS) in participants with relapsed and/or refractory multiple myeloma (RRMM) who have received at least 2 prior lines of therapy, including lenalidomide and a proteasome inhibitor, and are refractory to lenalidomide but not refractory to proteasome inhibitors.

Detailed Study Description

The drug being tested in this study is called Ixazomib. Ixazomib is being tested to treat people who have RRMM. This study will compare the efficacy and safety in participants who take ixazomib and dexamethasone to pomalidomide and dexamethasone. It is an open-label, phase 2 study that, on the basis of a prespecified go/no-go decision rule, will progress to a phase 3 registrational study.

The study will enroll approximately 300 patients. Participants will receive:

  • Ixazomib 4 mg + dexamethasone 20 mg (or 10 mg if participant is aged >=75 years) OR
  • pomalidomide 4 mg + dexamethasone 40 mg (or 20 mg if participant is aged >=75 years)

All participants will be asked to take either ixazomib plus dexamethasone (in cases where only 4 mg tablets for dexamethasone are available, the following dexamethasone schedule is recommended for participants aged >=75 years: 12 mg dexamethasone will be given on Days 1, 8, 15, and 22 of every 28-day cycle; and 8 mg dexamethasone will be given on Days 2, 9, 16, and 23 of every 28-day cycle) or pomalidomide 4 mg + dexamethasone 40 mg at recommended doses.

This multi-center trial will be conducted worldwide. The overall time to participate in this study is approximately 63 months if the phase 3 portion of the study is completed. Alternatively, if the no-go criteria are met during the phase 2 portion, the study will be completed approximately 22 to 29 months after the first participant enters the study.

Participants will make multiple visits to the clinic, and will be contacted for PFS follow-up, in case of study drug discontinuation for up to 7 years from first dose administration. After disease progression, participants will be followed-up for OS every 12 weeks until death or up to 10 years.

Clinical Study Identifier: NCT03170882

Find a site near you

Start Over

Highlands Oncology Group

Fayetteville, AR United States
  Connect »

St Joseph Heritage Healthcare

Santa Rosa, CA United States
  Connect »

Lynn Cancer Institute

Boca Raton, FL United States
  Connect »

University of Florida

Gainesville, FL United States
  Connect »

Mid Florida Cancer Center

Sanford, FL United States
  Connect »

University of Maryland

Baltimore, MD United States
  Connect »

Saint Agnes Hospital

Baltimore, MD United States
  Connect »

Henry Ford Health System

Detroit, MI United States
  Connect »

Michigan State University

Lansing, MI United States
  Connect »

Mayo Clinic

Rochester, MN United States
  Connect »

San Juan Oncology Associates

Farmington, NM United States
  Connect »

The Queen Elizabeth Hospital

Woodville South, Australia
  Connect »

Box Hill Hospital

Box Hill, Australia
  Connect »

Fakultni nemocnice Plzen

Plzen Lochotin, Czechia
  Connect »

CHRU Nancy

Vandoeuvre Les Nancy, France
  Connect »

Centre Hospitalier Fleyriat

Bourg-en- Bresse Cedex, France
  Connect »

CHRU Rennes

Rennes Cedex 9, France
  Connect »

City Clinical Hospital # 40

Moscow, Russian Federation
  Connect »

Addenbrooke s Hospital

Cambridge, United Kingdom
  Connect »

Royal Bournemouth Hospital

Bournemouth, United Kingdom
  Connect »

Kent and Canterbury Hospital

Canterbury, United Kingdom
  Connect »

GenesisCare Oxford

Oxford, United Kingdom
  Connect »

Royal Stoke University Hospital

Stoke-on-Trent, United Kingdom
  Connect »

Leicester Royal Infirmary

Leicester, United Kingdom
  Connect »

Singleton Hospital

Swansea, United Kingdom
  Connect »

New Cross Hospital

Wolverhampton, United Kingdom
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.